717 related articles for article (PubMed ID: 29725131)
1. Interleukin-6: designing specific therapeutics for a complex cytokine.
Garbers C; Heink S; Korn T; Rose-John S
Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
3. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
4. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
5. Targeting Interleukin-6 Signaling in Clinic.
Kang S; Tanaka T; Narazaki M; Kishimoto T
Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
7. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
10. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
12. The blockade of IL-6 signaling in rational drug design.
Adachi Y; Yoshio-Hoshino N; Nishimoto N
Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
[TBL] [Abstract][Full Text] [Related]
13. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
14. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
15. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
18. Physiological effects of modulating the interleukin-6 axis.
Schett G
Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii43-ii50. PubMed ID: 29982781
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy using IL-6 receptor as the target].
Nishimoto N
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
[TBL] [Abstract][Full Text] [Related]
20. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
